Celgene
| Type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 1986 (1986) |
| Founder | Sol J. Barer |
| Headquarters | Summit, New Jersey, U.S. |
| Key people | Robert J. Hugin (Executive Chairman) Mark Alles (CEO) |
| Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
| Revenue |  $15.281 billion (2018) |
| Net income | $4.046 billion (2018) |
| Total assets | $35.480 billion (2018) |
| Total equity |  $6.161 billion (2018) |
| Number of employees | 8,852 (2018) |
| Parent | Bristol Myers Squibb |
| Website | www.bms.com |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
For detailed contact information visit location pages below.
Celgene's locations around the world
Clinical Trials sponsored by Celgene
-
CelgeneCelgene Corporation완전한신경교종 | 고형종양 | 혈관면역모세포성 T세포 림프종 | 연골육종 | 간내 담관암종미국, 프랑스
-
CelgeneCelgene Corporation완전한
-
Celgene Corporation완전한다발성 골수종미국, 스페인, 호주, 캐나다, 영국, 이탈리아, 스위스, 불가리아, 폴란드, 우크라이나, 벨기에, 독일, 헝가리, 아일랜드, 이스라엘, 러시아 연방
-
Celgene Corporation완전한
-
Celgene Corporation종료됨
-
CelgeneCelgene Corporation완전한